Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR Files Hunter Syndrome Drug in Brazil
December 23, 2020
- Takeda, PeptiDream to Develop Peptide Drug Conjugates for Neuromuscular Diseases
December 23, 2020
- Nichi-Iko Stops Supply of Clinoril Due to Dissolution Issue
December 23, 2020
- Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections
December 23, 2020
- Sosei, GSK Seal Global Deal Targeting GI Disorders
December 22, 2020
- Xospata Fails to Hit Goal in PIII Combo Trial: Astellas
December 22, 2020
- FDA Approves Iclusig for Resistant/Intolerant CML
December 22, 2020
- Takeda Offloads 5 Non-Core Assets in China for US$322 Million
December 22, 2020
- Takeda Slated to Launch Japan PI/II for Moderna Shot in January
December 22, 2020
- Mirogabalin Hits Primary Endpoint in PIII for Central Neuropathic Pain After Spinal Cord Injury: Daiichi Sankyo
December 21, 2020
- Eisai's New Manufacturing Site Completed, Set to Begin Lenvima Production in FY2021
December 21, 2020
- Teijin Hooks Up with Chinese Firm on Small Molecule R&D
December 21, 2020
- Decision on Pfizer Vaccine Unlikely to Come before Japan Data Submission Slated by February
December 21, 2020
- Sanofi Files Sarclisa for Add'l Usage/Dosage in Japan
December 21, 2020
- Edirol Approved in China: Chugai
December 21, 2020
- Pfizer/BioNTech’s COVID-19 Vaccine Filed in Japan, Exceptional OK Eyed
December 18, 2020
- 5%-Plus Discrepancy Threshold for Off-Year Re-Pricing Draws Fire from Pharma, Wholesalers
December 18, 2020
- 2nd Death Reported for Tainted Itraconazole User, Doctor Says Causal Link Unlikely
December 18, 2020
- Otsuka Gets Japan, European Rights to Aurinia’s Lupus Nephritis Drug
December 18, 2020
- More Drug Makers Launching “Follow-on AGs”; Norvasc, Metgluco AGs Listed in December
December 18, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…